This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mexico's Cofece files collective lawsuit over drug price collusion

( October 30, 2024, 21:12 GMT | Official Statement) -- MLex summary: The Mexican Economic Competition Commission (Cofece) has initiated its first-ever collective action lawsuit against Casa Marzam, Casa Saba, Fármacos Nacionales, and the Association of Pharmaceutical Product Distributors of Mexico for allegedly colluding over a 10-year period. The companies are accused of agreeing to not distribute medications on certain days, limiting the quantity of drugs supplied to pharmacies, manipulating sale prices, and restricting discounts, actions that have reportedly decreased the availability of medications and inflated prices nationwide. Cofece estimates the damage to exceed 2 billion pesos (US $99.2 million). The commission is now seeking 2.316 billion pesos (US $114.9 million) in compensation to be allocated to IMSS-Bienestar.Statement follows below in Spanish:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections